
Loading, please wait...

Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates

Smoking cessation presents unique challenges for marginalized groups who often lack access to tailored support. Consequently, a recent pilot study evaluated the EQQUAL program as a specialized SGM smoking cessation intervention. Specifically, this avatar-led digital health program utilizes Acceptance and Commitment Therapy (ACT) to help sexual and gender minority (SGM) young adults quit smoking.
Researchers recruited 124 participants aged 18 to 30 for this randomized controlled pilot trial. The team divided the cohort into two groups to compare EQQUAL with the standard Smokefree.gov program. Both interventions provided users with a web application and integrated text messaging services. After three months, the team assessed smoking abstinence through biochemical verification.
Results indicated that EQQUAL users experienced significantly higher rates of biochemically-verified abstinence. Specifically, 11.1% of the EQQUAL arm remained abstinent compared to only 4.9% in the control group. Moreover, participants reported higher overall satisfaction scores and usability ratings with the tailored digital interface. However, the study found that users only completed an average of 1.4 out of 6 digital sessions.
Furthermore, the theory-based change processes did not show robust differences between the two study arms. This suggests that while the tailored content improves immediate abstinence, the mechanism of change requires further investigation. Therefore, clinicians suggest that increasing user engagement might further improve these promising cessation outcomes. This specialized SGM smoking cessation intervention represents a vital step toward reducing health disparities in tobacco use.
Culturally-tailored digital tools offer a scalable solution for high-risk populations. Clinicians should consider such tools to support diverse patient populations effectively, especially those who may avoid traditional healthcare settings due to stigma. While initial results are positive, practitioners should emphasize the importance of completing all digital sessions to maximize the program's benefits.
The EQQUAL program is specifically tailored for sexual and gender minority young adults. It uses an avatar-led interface and Acceptance and Commitment Therapy (ACT) to address the unique psychosocial stressors and barriers this population faces when quitting smoking.
In the pilot trial, the EQQUAL group achieved a biochemically-verified abstinence rate of 11.1%. In contrast, the control group using the Smokefree.gov program achieved a rate of only 4.9%.
Despite higher satisfaction, user engagement remained low, with participants completing an average of only 1.4 out of 6 sessions. Researchers believe that increasing this engagement is key to further improving cessation outcomes.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References

A randomized pilot trial evaluates EQQUAL, a digital health tool for SGM young adult smoking cessation, showing promising results over standard programs....
4 weeks back

A new in silico study using the DILIsym model reveals why Obeticholic Acid (OCA) faced liver safety hurdles in MASLD trials. The research highlights bile acid transporter inhibition as a key driver of hepatotoxicity, validating the FDA's cautious approach to OCA approval in metabolic liver diseases.
Today

This multiomics study reveals region-specific variations in the molecular composition of human milk fat globule membrane (HMFGM) proteins and their N-glycoprotein derivatives across China, highlighting the impact of regional diversity on breast milk composition.
Today

An alarming rise in heart attacks among young Indians in their 30s and 40s is closely linked to chronic stress, poor sleep, and processed food consumption. Leading cardiac surgeon Dr. Ramakanta Panda highlights the high risk faced by professionals in IT and finance, offering crucial insights for prevention.
Today

A new study evaluates a genipin-crosslinked gelatin/PVA hydrogel for delivering hydroxytyrosol to treat osteoarthritis. The GPVA5%-GNP formulation shows excellent biocompatibility and metabolic recovery in human chondrocytes, offering a potent localized therapy for cartilage regeneration.
Today

Recent research highlights METTL7B's role in driving papillary thyroid carcinoma (PTC) progression. By interacting with USP28 to stabilize HIF-1α, METTL7B enhances glycolytic activity and tumor growth, presenting a potential therapeutic target for advanced PTC cases.
Today